Nymox Pharmaceutical Corporation (NASDAQ:NYMX) Director James George Robinson acquired 5,000 shares of the business’s stock in a transaction dated Wednesday, August 2nd. The stock was bought at an average cost of $3.79 per share, with a total value of $18,950.00. Following the acquisition, the director now owns 3,077,550 shares in the company, valued at approximately $11,663,914.50. The purchase was disclosed in a filing with the SEC, which can be accessed through the SEC website.

James George Robinson also recently made the following trade(s):

  • On Thursday, August 3rd, James George Robinson acquired 10,000 shares of Nymox Pharmaceutical Corporation stock. The stock was bought at an average cost of $3.73 per share, with a total value of $37,300.00.
  • On Tuesday, August 1st, James George Robinson acquired 15,000 shares of Nymox Pharmaceutical Corporation stock. The stock was bought at an average cost of $3.72 per share, with a total value of $55,800.00.
  • On Thursday, July 6th, James George Robinson acquired 3,000 shares of Nymox Pharmaceutical Corporation stock. The stock was bought at an average cost of $3.92 per share, with a total value of $11,760.00.
  • On Wednesday, July 5th, James George Robinson acquired 5,000 shares of Nymox Pharmaceutical Corporation stock. The stock was bought at an average cost of $3.97 per share, with a total value of $19,850.00.
  • On Friday, July 7th, James George Robinson acquired 11,500 shares of Nymox Pharmaceutical Corporation stock. The stock was bought at an average cost of $4.00 per share, with a total value of $46,000.00.
  • On Wednesday, June 28th, James George Robinson purchased 8,500 shares of Nymox Pharmaceutical Corporation stock. The shares were acquired at an average cost of $4.09 per share, with a total value of $34,765.00.
  • On Monday, June 26th, James George Robinson purchased 15,000 shares of Nymox Pharmaceutical Corporation stock. The shares were acquired at an average cost of $3.80 per share, with a total value of $57,000.00.
  • On Tuesday, June 20th, James George Robinson purchased 5,000 shares of Nymox Pharmaceutical Corporation stock. The shares were acquired at an average cost of $3.76 per share, with a total value of $18,800.00.
  • On Monday, June 19th, James George Robinson purchased 5,000 shares of Nymox Pharmaceutical Corporation stock. The shares were acquired at an average cost of $3.79 per share, with a total value of $18,950.00.
  • On Wednesday, June 21st, James George Robinson acquired 15,000 shares of Nymox Pharmaceutical Corporation stock. The shares were purchased at an average price of $3.77 per share, for a total transaction of $56,550.00.

Shares of Nymox Pharmaceutical Corporation (NASDAQ NYMX) traded down 1.35% on Friday, hitting $3.66. The company had a trading volume of 58,076 shares. The company has a 50 day moving average price of $3.96 and a 200 day moving average price of $3.79. The firm’s market capitalization is $184.64 million. Nymox Pharmaceutical Corporation has a 1-year low of $1.62 and a 1-year high of $5.79.

ILLEGAL ACTIVITY NOTICE: “Insider Buying: Nymox Pharmaceutical Corporation (NASDAQ:NYMX) Director Buys 5,000 Shares of Stock” was first published by American Banking News and is owned by of American Banking News. If you are viewing this news story on another publication, it was illegally stolen and reposted in violation of United States and international copyright & trademark legislation. The original version of this news story can be viewed at https://www.americanbankingnews.com/2017/08/04/insider-buying-nymox-pharmaceutical-corporation-nasdaqnymx-director-buys-5000-shares-of-stock.html.

Separately, ValuEngine cut Nymox Pharmaceutical Corporation from a “hold” rating to a “sell” rating in a research report on Monday, July 24th.

Hedge funds have recently modified their holdings of the company. Bank of New York Mellon Corp bought a new stake in shares of Nymox Pharmaceutical Corporation during the second quarter worth about $323,000. Wedbush Securities Inc. boosted its stake in shares of Nymox Pharmaceutical Corporation by 30.6% in the second quarter. Wedbush Securities Inc. now owns 234,692 shares of the biopharmaceutical company’s stock worth $1,033,000 after buying an additional 55,000 shares during the period. Rhumbline Advisers bought a new stake in shares of Nymox Pharmaceutical Corporation during the second quarter worth about $134,000. Finally, Schwab Charles Investment Management Inc. bought a new stake in shares of Nymox Pharmaceutical Corporation during the second quarter worth about $222,000. 1.78% of the stock is currently owned by institutional investors and hedge funds.

Nymox Pharmaceutical Corporation Company Profile

Nymox Pharmaceutical Corporation, formerly Corporation Pharmaceutique Nymox, is a biopharmaceutical company. The Company is focused on developing its drug candidate, NX-1207, for the treatment of benign prostatic hyperplasia (BPH) and the treatment of low-grade localized prostate cancer. The Company markets NicAlert and TobacAlert tests that use urine or saliva to detect use of tobacco products.

Insider Buying and Selling by Quarter for Nymox Pharmaceutical Corporation (NASDAQ:NYMX)

Receive News & Ratings for Nymox Pharmaceutical Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nymox Pharmaceutical Corporation and related companies with MarketBeat.com's FREE daily email newsletter.